Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
Starna Therapeutics, a clinical-stage mRNA drug developer based in Suzhou, announced the completion of a...
Starna Therapeutics, a clinical-stage mRNA drug developer based in Suzhou, announced the completion of a...
Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has...
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...